| Incretin hormones: Their role in health and disease |
70 |
| Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis |
65 |
| Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease |
42 |
| Identification of barriers to insulin therapy and approaches to overcoming them |
38 |
| GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials |
35 |
| Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis |
35 |
| Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials |
35 |
| Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review |
35 |
| Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial |
33 |
| Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study |
33 |
| Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET) |
32 |
| Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers |
32 |
| A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials |
31 |
| Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy |
31 |
| Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D) |
31 |
| A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials |
30 |
| Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study |
29 |
| Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study |
26 |
| Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014 |
26 |
| Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes |
25 |
| Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials |
25 |
| Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review |
24 |
| Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: A 2-year randomized clinical trial |
23 |
| Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes |
23 |
| Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease |
23 |
| Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study |
22 |
| Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component? |
22 |
| Biosynthesis, structure, and folding of the insulin precursor protein |
22 |
| Gaps to bridge: Misalignment between perception, reality and actions in obesity |
21 |
| Uric acid and the cardio-renal effects of SGLT2 inhibitors |
21 |
| Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol |
21 |
| Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study |
20 |
| Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes |
20 |
| Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide |
19 |
| Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin |
19 |
| Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW) |
19 |
| Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis |
19 |
| A novel GIP analogue, ZP enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents |
18 |
| Performance of the Freestyle Libre flash glucose monitoring (flash GM) system in individuals with type 1 diabetes: A secondary outcome analysis of a randomized crossover trial |
18 |
| Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial |
18 |
| Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol |
18 |
| Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study |
18 |
| Differential effects of the circadian system and circadian misalignment on insulin sensitivity and insulin secretion in humans |
18 |
| Epigenetic effects of metformin: From molecular mechanisms to clinical implications |
18 |
| A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors |
17 |
| Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials |
17 |
| Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial |
17 |
| Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications |
17 |
| Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study |
17 |
| Mobile phone applications and self-management of diabetes: A systematic review with meta-analysis, meta-regression of 21 randomized trials and GRADE |
17 |
